Financial Performance - Q3 2025 revenue increased 22% year-over-year to $26.1 million, up from $21.3 million in Q3 2024[5] - Q3 2025 gross profit rose 30% year-over-year to $17.5 million, compared to $13.4 million in Q3 2024[5] - GAAP net income for Q3 2025 was $0.8 million, or $0.04 per share, reversing from a net loss of $(9.1) million, or $(0.50) per share in Q3 2024[5] - Non-GAAP net income for Q3 2025 totaled $3.9 million, or $0.20 per diluted share, compared to $2.3 million, or $0.12 per diluted share in Q3 2024[5] - Adjusted EBITDA for Q3 2025 increased to $5.1 million, up from $2.7 million in the same period last year[5] - Net revenue for the three months ended September 30, 2025, was $26,067 million, a 22.5% increase from $21,309 million in the same period of 2024[24] - Gross profit for the nine months ended September 30, 2025, reached $49,495 million, compared to $37,355 million for the same period in 2024, reflecting a 32.4% increase[24] - The company reported a net income of $779 million for the three months ended September 30, 2025, compared to a net loss of $9,124 million in the same period of 2024[24] - Non-GAAP net income for the nine months ended September 30, 2025, was $9,960 million, compared to $6,200 million for the same period in 2024, an increase of 60.3%[29] - Adjusted EBITDA for the nine months ended September 30, 2025, was $12,326 million, compared to $2,882 million for the same period in 2024, indicating a substantial increase[30] Guidance and Projections - Full year 2025 revenue guidance increased to a range of $105 million to $109 million, with adjusted EBITDA guidance of $16 million to $19 million[1][7] - 2026 revenue guidance introduced at a range of $118 million to $124 million, with adjusted EBITDA expected between $19 million and $22 million[1][7] Cash and Operating Activities - Cash and cash equivalents as of September 30, 2025, totaled $19.5 million, up from $13.4 million as of December 31, 2024[5] - Cash provided by operating activities for the nine months ended September 30, 2025, was $11,627 million, significantly higher than $4,691 million in the same period of 2024[26] - The company reported a net increase in cash and cash equivalents of $6,139 million for the nine months ended September 30, 2025, compared to $2,274 million in the same period of 2024[26] Operating Expenses - Operating expenses decreased to $15,466 million for the three months ended September 30, 2025, down from $22,009 million in the same period of 2024, a reduction of 29.8%[24] - Total operating expenses for the nine months ended September 30, 2025, were $46,371 million, down from $54,695 million in the same period of 2024, a decrease of 15.2%[24] Revenue Metrics - Net revenue retention for the twelve months ended September 30, 2025, was 120%, down from 127% in the previous year[6] - Average revenue per top 20 pharmaceutical manufacturer increased to $3,073, compared to $2,874 in the prior year[6]

Core Insights - OptimizeRx Corp. reported a Q3 revenue of $26.1 million, reflecting a 22% year-over-year increase, and a gross profit of $17.5 million, which is a 30% increase compared to the same period last year [1][5] Financial Performance - The company achieved a GAAP net income of $0.8 million, or $0.04 per share, in Q3 2025, compared to a net loss of $(9.1) million, or $(0.50) per share, in Q3 2024 [5][19] - Non-GAAP net income for Q3 2025 was $3.9 million, or $0.20 per diluted share, up from $2.3 million, or $0.12 per diluted share, in Q3 2024 [5][24] - Adjusted EBITDA for Q3 2025 increased to $5.1 million from $2.7 million in the same period last year [5][24] Guidance and Outlook - The company raised its full-year 2025 revenue guidance to a range of $105 million to $109 million and adjusted EBITDA guidance to between $16 million and $19 million [4][6] - For 2026, OptimizeRx introduced guidance with expected revenue between $118 million and $124 million and adjusted EBITDA between $19 million and $22 million [4][6] Key Performance Indicators - Average revenue per top 20 pharmaceutical manufacturer increased to $3.073 million in 2025 from $2.874 million in 2024 [3] - The percentage of total revenue attributable to the top 20 pharmaceutical manufacturers decreased to 56% in 2025 from 65% in 2024 [3] - Net revenue retention was reported at 120% for 2025, down from 127% in 2024 [3] Cash Position - As of September 30, 2025, cash, cash equivalents, and short-term investments totaled $19.5 million, compared to $13.4 million at the end of 2024 [5][21] Management Commentary - The CEO highlighted strong, profitable growth and an optimistic outlook for 2026, attributing success to execution, customer outcomes, and market-leading technologies [3]

Core Insights - OptimizeRx Corp. will hold a conference call on November 6, 2025, to discuss its third-quarter financial results for the period ending September 30, 2025 [1][2] - The call will include a question-and-answer session and will be accessible via toll-free and international numbers [2] - A replay of the call will be available for 12 months on the company's investor relations website [3] Company Overview - OptimizeRx is a leading healthcare technology company focused on enhancing connections between life science brands, patients, and healthcare providers [4] - The company utilizes AI-driven tools such as the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to facilitate timely and relevant engagement [4] - OptimizeRx emphasizes privacy-safe, patient-centric technology to ensure impactful interactions that deliver therapies to patients effectively [5] - The company is headquartered in Waltham, Massachusetts, and collaborates with major pharmaceutical and life sciences companies to improve healthcare outcomes [5]

Core Insights - OptimizeRx Corporation (NASDAQ: OPRX) is perceived as a simple messaging platform within Electronic Health Record (EHR) systems, but it is evolving into a clinical data provider [1] Company Overview - OPRX is transitioning from being merely a delivery channel to a more comprehensive role in clinical data analysis [1]

Group 1 - OptimizeRx Corporation (NASDAQ: OPRX) is perceived as a simple messaging platform within Electronic Health Record (EHR) systems, but it is evolving beyond just being a delivery channel [1] - The company aims to transform its role to connect pharmaceutical companies with healthcare providers more effectively [1]

Core Viewpoint - OptimizeRx Corp. (OPRX) is identified as a strong momentum stock with a Zacks Rank of 1 (Strong Buy) and a Momentum Style Score of B, indicating potential for significant near-term gains [4][12]. Company Performance - OPRX shares have increased by 3.19% over the past week, while the Zacks Computer - Software industry has declined by 1.15% during the same period [6]. - Over the last quarter, OPRX shares have risen by 40.18%, and over the past year, they have surged by 150.07%, significantly outperforming the S&P 500, which has moved 8.57% and 18.94% respectively [7]. - The average 20-day trading volume for OPRX is 371,193 shares, indicating a bullish trend as the stock is rising with above-average volume [8]. Earnings Outlook - In the past two months, four earnings estimates for OPRX have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $0.53 to $0.67 [10]. - For the next fiscal year, four estimates have also moved upwards without any downward revisions, suggesting a positive earnings outlook [10].

Group 1: OptimizeRx Performance - OptimizeRx (OPRX) reported second-quarter 2025 revenues of $29.2 million, reflecting a 55% year-over-year increase, with earnings per share at 24 cents, surpassing consensus estimates [1] - The company achieved strong adjusted EBITDA of $5.8 million and expanding gross margins, indicating operational leverage, while raising full-year revenue guidance to $104-$108 million [1] - Contracted revenues increased by over 30%, demonstrating growing customer confidence in OPRX's integrated solutions [1] Group 2: Strategic Focus and Market Position - OPRX's strategy centers on AI-driven workflow integration, utilizing an omnichannel platform that connects physicians, patients, and life sciences firms in real time [2] - The integration is crucial as the pharmaceutical industry focuses on efficient script lift and reduced abandonment amid regulatory uncertainty and a shift towards specialty medications [3] - Management noted that operating expenses remained flat despite double-digit top-line growth, indicating meaningful leverage from its scalable tech stack [3] Group 3: Future Outlook and Challenges - Part of the second-quarter outperformance was due to episodic managed service revenues, which are not expected to recur in the second half of the year [4] - OPRX's ability to serve both healthcare professionals (HCP) and direct-to-consumer (DTC) markets at scale provides a competitive advantage, but sustaining momentum will require expanding multiyear subscription contracts and managing customer concentration risk [4] - Average revenues per top-20 pharma manufacturer increased to $3.1 million, with mid-tier clients scaling faster than top-20 accounts, broadening the revenue base [5] Group 4: Industry Trends and Competitors - Omnicell (OMCL) is enhancing its digital health strategy through the Intelligence-Enabled Pharmacy vision, scaling its OmniSphere platform, which is a cloud-based, AI-powered solution for predictive analytics and real-time medication inventory management [6] - OMCL's Advanced Services suite integrates automation, analytics, and remote pharmacy services to optimize clinical and financial outcomes for healthcare providers [7] - Teladoc Health (TDOC) is focusing on digital mental health through its BetterHelp platform and the acquisition of UpLift, which enhances therapy options and reduces out-of-pocket costs for users [8]

Core Insights - OptimizeRx Corp. will participate in the 9th Annual Lake Street Capital Best Ideas Growth Conference on September 11, 2025, in New York, NY [1] - The company is a leading provider of healthcare technology solutions that help life sciences companies engage healthcare professionals and patients [1][3] Company Overview - OptimizeRx utilizes AI-driven tools such as the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to enhance engagement strategies [3] - The company focuses on creating synchronized marketing solutions that facilitate faster treatment decisions and improve patient outcomes [3] - OptimizeRx is committed to privacy-safe, patient-centric technology, ensuring impactful interactions that deliver therapies to the right patients at the right time [4] - The company partners with leading pharmaceutical and life sciences companies to transform the healthcare landscape [4]

Core Insights - The partnership between OptimizeRx and Lamar Advertising aims to enhance out-of-home (OOH) advertising for healthcare brands by integrating OptimizeRx's Micro-Neighborhood Targeting (MNT) data with Lamar's extensive advertising inventory [1][2][3] Group 1: Partnership Overview - OptimizeRx's MNT data allows for targeted advertising based on disease prevalence at the ZIP+4 level, enabling precise geographic targeting for healthcare brands [2][7] - The collaboration is designed to make OOH advertising a strategic component of omnichannel marketing strategies, allowing brands to reach relevant patient populations effectively [2][5] Group 2: Industry Impact - This partnership positions OOH advertising as a viable alternative for life sciences brands amidst the competitive digital marketing landscape, leveraging real-world clinical data for targeted outreach [5][6] - The integration of MNT data with Lamar's inventory provides healthcare marketers with a data-driven approach to media planning, allowing for prioritization of advertising spend based on local health attributes [3][5] Group 3: Benefits of the Partnership - The partnership offers a cost-effective solution that competes with linear TV placements while delivering measurable results through targeted OOH advertising [6][7] - The vast reach of Lamar's network, combined with OptimizeRx's clinical targeting, enables healthcare brands to expand their marketing strategies beyond digital channels confidently [7][8]

Company Overview - OptimizeRx Corp. (OPRX) currently holds a Momentum Style Score of B, indicating potential for strong performance in the momentum investing strategy [3][12] - The company has a Zacks Rank of 1 (Strong Buy), which is associated with a strong track record of outperformance in the market [4][12] Price Performance - OPRX shares have increased by 4.75% over the past week, while the Zacks Computer - Software industry has remained flat during the same period [6] - Over the past month, OPRX's price has risen by 44.56%, significantly outperforming the industry's 0.45% [6] - In the last quarter, OPRX shares rose by 23.6%, and over the past year, they have surged by 117.45%, compared to the S&P 500's increases of 9.68% and 16.9%, respectively [7] Trading Volume - The average 20-day trading volume for OPRX is 481,960 shares, which serves as a useful baseline for price-to-volume analysis [8] Earnings Outlook - In the past two months, four earnings estimates for OPRX have been revised upwards, with no downward revisions, leading to an increase in the consensus estimate from $0.53 to $0.67 [10] - For the next fiscal year, four estimates have also moved upwards without any downward revisions [10]